



Product Information Sheet for Product No. 1021.0101.0201

For *in vitro* academic research use only.

Not for use in diagnostic applications.

Not for use in humans.

Not for re-sale or re-import.

Human Prion Protein (23–230), native in water

Source	Recombinantly expressed in <i>E. coli</i> from a plasmid vector containing a DNA sequence encoding human prion protein of amino acid residues 23–230 (see also UniProt P04156).
Amino acid sequence	GSKKRPKPGGWNTGGSRYPGQGS PGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGGLGGYMLGSAMSRPI I HFGSDYEDRYRENMHRYPNQVYRPMDEYSNQNNFVHDCVNI TIKQHTVTTTTKGEN FTETDVKMMERVVEQMCITQYERESQAYYQGRS
Molecular weight	22891 g · mol ⁻¹
Chain length	210 amino acids
Purity	> 95% by SDS-PAGE
Supply	Finally dialysed in pure water, shock frozen in liquid nitrogen at 250 µg per vial.
Storage	– 80°C
Thawing	Gentle agitation at 37°C until no ice is left. Keep on ice. Do not refreeze.
Description	Prion Protein (PrP) is an abundant cellular protein in mammalian neural tissue. It is associated with mammalian prion diseases, e.g. transmissible spongiforme encephalopathies that include human Creutzfeld-Jakob disease, bovine spongiforme encephalopathy, sheep scrapie, cervid's chronic wasting disease and various rodent prion diseases. In the disease process, PrP undergoes protein aggregation into disease specific PrP ^{Sc} .
Applications	Prion Protein is frequently used in analytical aggregation assays (Refs. 4 & 5)
Production	Product of Germany.
Term & Conditions	SeNostic terms & conditions (AGB) as of the date of product order apply. Go to www.senostic.com for details.
Disclaimer	Wildtype mammalian prion proteins including this product are L1 biological materials in the country of origin. By purchasing or using this product you certify that you are qualified to work with prion proteins and that you will do so only in accordance with your county's regulations. You further certify that you are aware that mammalian prions are L3 biological materials, and that you will carry out any work that could result in aggregated or infectious prions (see for example refs. 4 & 5) exclusively under appropriate biological safety conditions in accordance with all applicable local regulations. YOU AGREE THAT SENOSTIC WILL NOT BE LIABLE FOR ANY DAMAGES THAT RESULT FROM THE INTENTIONAL OR UNINTENTIONAL GENERATION OF AGGREGATED OR INFECTIOUS PRIONS FROM THIS PRODUCT. If you have further questions about this product or are uncertain about the terms of use, please contact info@senostic.com

References

1. Zahl et al., NMR solution structure of the human prion protein. *Proc. Natl. Acad. Sci. U.S.A.* 2000;97(1):145-50.
2. López Garcia et al. NMR structure of the bovine prion protein. *Proc Natl Acad Sci U S A.* 2000;97(15):8334-9.
3. Riek et al., NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). *FEBS Lett.* 1997;413(2):282-8
4. Lühns et al., Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions. *J. Mol. Biol.* 2006; 357(3):833-41.
5. Atarshi et al., Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. *Nat Methods.* 2008;5(3):211-2.